Compare Abbott Laboratories (ABT) vs Simon Property Group Inc (SPG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Simon Property Group Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Simon Property Group Inc trades at $219.09 (market cap $73.68B). The key difference: Abbott Laboratories is far larger — about 2.3× Simon Property Group Inc's market cap, and Simon Property Group Inc pays the higher dividend (3.87%). Which is the better fit depends on your goals.
| ABT | SPG | |
|---|---|---|
Market Cap | $166.94B | $73.68B |
Sector | Health | Real Estate |
52-Week High | $136.62 | $227.56 |
52-Week Low | $82.57 | $159.93 |
Enterprise Value | $193.69B | $102.16B |
Dividend Yield | 2.63% | 3.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Simon Property Group (SPG) trades at $227.19, up 0.5% on the day, with strong technical momentum as the stock approaches key resistance near $228. The REIT demonstrates robust fundamentals with Q1 2026 earnings beating expectations, revenue growth accelerating to $6.36B in 2025, and exceptional profitability metrics including 70.59% net income margin and 127.05% ROE. Recent corporate developments include a $2.25 dividend payment and Euro-denominated note offering, while analyst sentiment remains mixed despite strong operational performance.
SPG presents a compelling investment case with premium mall assets generating strong cash flows and dividend income, though elevated valuation multiples and significant debt levels warrant caution. The stock's current price above the $211.30 consensus target suggests limited near-term upside, while e-commerce competition and interest rate sensitivity represent ongoing headwinds for the retail REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
